PoPPI is a £3.4 million five-year collaborative programme, funded by the Engineering and Physical Sciences Research Council (EPSRC), between the

​University of Leeds

University of Bristol

Northern Institute for Cancer Research (Newcastle University)

AstraZeneca

Domainex

The programme focuses on the development of computational and chemical tools to classify protein-protein interactions (PPI) and use the resultant insight to synthesize molecules, which act as selective inhibitors and, which can be used as chemical probes. Understanding and modulating the PPIs will increase the knowledge of the underlying mechanisms of diseases, such as cancer and the neurodegenerative diseases, e.g. Alzheimer’s, Huntingdon’s and Parkinson’s.